Apellis Reports Results of Pegcetacoplan in P-III (DERBY and OAKS) Studies for Geographic Atrophy (GA)
Shots:
- The P-III DERBY and OAKS studies evaluate the efficacy and safety of intravitreal pegcetacoplan vs sham in 621 and 637 patients with GA or secondary to AMD respectively
- Both monthly and every-other-mos. pegcetacoplan continued to reduce GA lesion @18mos. with all p-values (nominal) below 0.05. Therapy showed potential for improving treatment effects over time
- In OAKS & DERBY, reduction in GA lesion growth with both monthly (22% & 13%) and every other mos. treatment (16% & 12%) respectively. Additionally, The company plans to submit the NDA to the US FDA in Q2’22
Ref: Apellis | Image: Apellis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
